McGuireWoods Consulting today announced that Gena McGroarty was promoted to vice president of MWCAdvocacy effective January 1.
McGuireWoods Consulting announced today it has opened a Tallahassee office with the arrival of veteran lobbyists Sean Stafford, Rhett O’Doski and Ryder Rudd.
McGuireWoods Romania celebrated its 10th anniversary in Bucharest with a client reception on December 5, 2017.
McGuireWoods Consulting President L.F. Payne and Executive Vice President and Chairman-elect Mark Bowles were recently tapped to serve on Virginia Governor-elect Ralph Northam’s Transition Committee. Mark has also been named a co-chair of the Inaugural Committee.
McGuireWoods’ Board of Partners has elected Jonathan P. Harmon to succeed Richard Cullen as McGuireWoods’ chairman. In addition, the board appointed J. Tracy Walker IV to follow Thomas E. Cabaniss as the firm’s managing partner.
Bill of the Week: Tax Cuts 2.0
Well…it’s not going to be an actual bill: Ways and Means Chairman Kevin Brady (R-TX) will release an outline for Tax Cuts 2.0 before the House departs for August recess this week. House GOP tax writers are meeting one more time before the rollout.
This Week: More rules to OMB…House overhauls OTC drug rules…HELP Committee looks at drug costs…FDA outlines reorganization
Your weekly North Carolina political news report.
Final day for early voting - what you should know
Word of the Week: Bureaucracy
The OMB and Treasury issued a memorandum of agreement (MOA) in April that established a new interagency process for reviewing certain tax regulations, namely those stemming from the 2017 GOP tax law. And things are working as expected…
GA-18-380: This report examines the progress the progress the Veterans Health Administration (VHA) has made improving opioid safety through its Opioid Safety Initiative (OSI).
An overview of the upcoming week in Congress from the McGuireWoods Consulting Tax Policy Update Team.
This month, President Trump announced his plan to lower drug prices. The plan does not call for a major overhaul of drug companies’ pricing practices, but does include some proposals that they oppose. Much of Trump’s plan is in the form of suggested actions, and it will take time for actual detailed proposals to be put forward.